ClinicalTrials.gg
CompletedNCT00081458Updated Jun 9, 2021Results posted

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome

A Phase 3 interventional study of Placebo and Teduglutide 0.05 mg/kg/d in Short Bowel Syndrome, sponsored by Shire. Completed at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
3rd of 20
84 · median 20
Started
2004
the only one that year
Phase 3
16 of 20
none open now
Registered
1st of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 16 in phase 3, and was the 1st registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of teduglutide compared with placebo in subjects with parenteral nutrition (PN)-dependent short bowel syndrome (SBS).

Read the detailed description

Teduglutide is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the growth, proliferation, and maintenance of cells lining the gastrointestinal tract. Teduglutide has been shown in animal studies and previous human clinical trials to increase the size and number of these cells, thereby increasing the absorptive surface area of the intestines.

The multicenter, double-blind, international Phase III trial will randomly assign approximately 80 patients to receive daily subcutaneous injections of 0.05 milligrams or 0.10 milligrams of teduglutide per kilogram of body weight, or a placebo. Dosing will continue for a period of six months. The primary endpoint in the study is a reduction in the use of intravenous feeding, which is often required to sustain life in patients with SBS.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Short Bowel Syndrome
  • Parenteral Nutrition
  • SBS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged 18 years of age or older at the time of signing the form (ICF)
  • SBS as a result of major intestinal resection resulting in at least 12 months intravenous feeding
  • Body weight must be less than 90 kg
  • At baseline, subjects must require PN treatment to meet their caloric or electrolyte needs due to ongoing malabsorption at least 3 times weekly and to be on a stable PN regimen for 4 weeks before dosing
  • (BMI) 18 to 27 kg/m2
  • Adequate hepatic and renal function

Exclusion criteria

Exclusion Criteria:

  • History of cancer or lymphoproliferative disease with fewer than 5 years documented disease-free state
  • History of alcohol or drug abuse (within previous year)
  • Participation in a clinical study within 30 days prior to signing the ICF, or concurrent participation in any clinical study
  • Clinically significant laboratory abnormalities at the time of randomization
  • Previous use of teduglutide (ALX-0600)
  • Prior use of native GLP-2 within 3 months of screening visit
  • Hospital admission within 1 month prior to screening visit
  • Pregnant or lactating women
  • Any condition or circumstance, which in the investigator's opinion would put the subject at any undue risk, prevent completion of the study, or interfere with analysis of the study results.
  • Presence of excluded disease: Radiation enteritis, Scleroderma, Celiac disease, /Tropical sprue, Pseudo-obstruction, Active inflammatory bowel disease (IBD), Pre-malignant/malignant change in colonoscopy or polypectomy, Surgery scheduled within the time frame of the study, (HIV) positive test, Immunological disorders, Possible allergies to teduglutide or its constituents, Significant, active, uncontrolled, untreated systemic diseases
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Placebo injectable subcutaneously daily into the thigh or abdomen

    Drug: Placebo

  • Experimental
    2

    teduglutide 0.05 mg/kg/d

    Drug: Teduglutide 0.05 mg/kg/d

  • Experimental
    3

    teduglutide 0.1 mg/kg/d

    Drug: Teduglutide 0.1 mg/kg/d

Interventions

  • DrugPlacebo

    placebo injectable subcutaneously daily into thigh or abdomen

  • DrugTeduglutide 0.05 mg/kg/d

    Drug page: Teduglutide

    Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen

    Also known as: GATTEX

  • DrugTeduglutide 0.1 mg/kg/d

    Drug page: Teduglutide

    Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen

    Also known as: GATTEX

06

What researchers measure

Primary outcomes

  1. A Graded Response Score in Parenteral Nutrition (PN) Reduction

    The intensity of the response relied on a reduction from Baseline in weekly parenteral nutrition (PN) volume (minimum reduction of 20% and a maximum of 100%). Duration of the response incorporated responses at Weeks(Wk) 16-20 and at Wk20-24. Zero (0 - lowest) assigned if \<20% reduction at Wk20-24 and reduction at Wk16-20 of \< 20%, 20-39%, or \>=40%. One (1) assigned if reduction of 20-39% at Wk20-24 but \< 20% at Wk16-20. Two(2) assigned if reductions of 40-99% at Wk20-24 AND \<20% at Wk16-20 OR 20-39% at Wk20-24 AND 20-39% at Wk16-20. Three (3) assigned if reductions of 100% at Wk20-24 AND \<20% at Wk16-20 OR 40-99% at Wk20-24 AND 20-39% at Wk16-20 OR 20-39% at Wk20-24 AND \>=40% at Wk16-20. Four (4) assigned if reductions of 100% at Wk20-24 AND 20-39% at Wk16-20 OR 40-99% at Wk20-24 AND \>=40% at Wk16-20.

    Time frame: 6 months

Secondary outcomes

  1. Number of Subjects Achieving Binary Response at Week 20, Maintained at Week 24

    An efficacy responder was defined as achieving at least a 20% reduction from Baseline to Week 20 and maintained at Week 24 in weekly actual PN infusion volume.

    Time frame: 6 months of treatment

07

Results

Posted Jul 15, 2013

Participant flow

First subject was screened 25May2004 and last subject evaluations were completed on 06Jul2007.

Participant flow — Overall Study
MilestonePlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/d
Started163533
Received treatment163532
Completed152729
Not completed184
Withdrew: Adverse event152
Withdrew: Withdrawal by subject031
Withdrew: Randomized but not dosed001

Outcome measures

PrimaryA Graded Response Score in Parenteral Nutrition (PN) Reduction

The intensity of the response relied on a reduction from Baseline in weekly parenteral nutrition (PN) volume (minimum reduction of 20% and a maximum of 100%). Duration of the response incorporated responses at Weeks(Wk) 16-20 and at Wk20-24. Zero (0 - lowest) assigned if \<20% reduction at Wk20-24 and reduction at Wk16-20 of \< 20%, 20-39%, or \>=40%. One (1) assigned if reduction of 20-39% at Wk20-24 but \< 20% at Wk16-20. Two(2) assigned if reductions of 40-99% at Wk20-24 AND \<20% at Wk16-20 OR 20-39% at Wk20-24 AND 20-39% at Wk16-20. Three (3) assigned if reductions of 100% at Wk20-24 AND \<20% at Wk16-20 OR 40-99% at Wk20-24 AND 20-39% at Wk16-20 OR 20-39% at Wk20-24 AND \>=40% at Wk16-20. Four (4) assigned if reductions of 100% at Wk20-24 AND 20-39% at Wk16-20 OR 40-99% at Wk20-24 AND \>=40% at Wk16-20.

Time frame:
6 months
Reported as:
Number · participants
A Graded Response Score in Parenteral Nutrition (PN) Reduction
participantsPlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/d
0 (No Response)151924
1062
2164
4022
5 (No longer need PN)020
Statistical analysis
  • Placebo vs Teduglutide 0.05 mg/kg/d vs Teduglutide 0.1 mg/kg/d · ANCOVA · p = 0.007
SecondaryNumber of Subjects Achieving Binary Response at Week 20, Maintained at Week 24

An efficacy responder was defined as achieving at least a 20% reduction from Baseline to Week 20 and maintained at Week 24 in weekly actual PN infusion volume.

Time frame:
6 months of treatment
Reported as:
Number · participants
Number of Subjects Achieving Binary Response at Week 20, Maintained at Week 24
participantsPlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/d
Responder1 (0 to 18.1)16 (29.2 to 62.2)8 (10.0 to 40.0)
Non-Responder15 (0 to 0)19 (0 to 0)24 (0 to 0)
Statistical analysis
  • Placebo vs Teduglutide 0.05 mg/kg/d vs Teduglutide 0.1 mg/kg/d · ANCOVA · p = 0.005

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/16 (31.3%)15/16 (93.8%)
Teduglutide 0.05 mg/kg/d—13/35 (37.1%)33/35 (94.3%)
Teduglutide 0.1 mg/kg/d—11/32 (34.4%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/d
Catheter related complicationGeneral disorders3/160/353/32
Catheter sepsisInfections and infestations1/163/354/32
Catheter bacteraemiaInfections and infestations1/161/350/32
Device failureInjury, poisoning and procedural complications1/160/351/32
Eye InjuryInjury, poisoning and procedural complications1/160/350/32
Back painMusculoskeletal and connective tissue disorders1/160/350/32
Intervertebral discitisMusculoskeletal and connective tissue disorders1/160/350/32
PneumothoraxRespiratory, thoracic and mediastinal disorders1/160/350/32
PyrexiaGeneral disorders0/162/350/32
Catheter site infectionInfections and infestations0/162/350/32
Most frequent other events
Showing 10 of 25
Most frequent other events
EventPlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/d
NauseaGastrointestinal disorders4/165/3510/32
Abdominal painGastrointestinal disorders2/167/359/32
HeadacheNervous system disorders1/169/357/32
Injection site bruisingGeneral disorders0/161/357/32
Catheter related complicationsGeneral disorders3/161/353/32
Injection site erythemaGeneral disorders0/161/356/32
VomitingGastrointestinal disorders2/164/356/32
Urinary tract infectionInfections and infestations3/163/355/32
abdominal distensionGastrointestinal disorders0/166/353/32
NasopharyngitisInfections and infestations2/166/355/32

Baseline characteristics

84 subjects were initially randomized; however, one subject never received study therapy. As a result, the total participant who started flow period is 83.

Age, Continuous
Age, Continuous(years)PlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/dTotal
Mean49.4 ± 15.147.1 ± 14.250.3 ± 14.048.8 ± 14.2
Age, Customized
Age, Customized(Participants)PlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/dTotal
< 35 years37515
35-44 years25411
45 - 54 years3121025
> 55 years8111332
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/dTotal
Female9181946
Male7171337
Region of Enrollment
Region of Enrollment(Participants)PlaceboTeduglutide 0.05 mg/kg/dTeduglutide 0.1 mg/kg/dTotal
Belgium1102
Canada1258
Denmark2338
France2529
Germany0022
Netherlands0415
Poland36817
United Kingdom0314
United States7111028
08

Study locations

32 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Georgetown University
    Washington, District of Columbia 20007, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northwestern Center for Clinical Research
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania - Penn Nursing
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • l'Hôpital Erasme
    Brussels, 1070, Belgium
  • Royal Alexandra Hospital
    Edmonton, Alberta T5H4B9, Canada
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z1Y6, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B1W8, Canada
  • Toronto General Hospital
    Toronto, Ontario M5G2N2, Canada
  • Rigshospitalet, University of Copenhagen
    Copenhagen, 2100, Denmark
  • Hôpital Claude-Huriez
    Lille, 59037, France
  • Hôpital de la Croix-Rousse
    Lyon, 69317, France
  • Hôpital Edouard Herriot
    Lyon, 69437, France
  • Hôpital Beaujon
    Paris, 92110, France
  • Charité University Hospital
    Berlin, 10117, Germany
  • Charité-Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Academic Medical Center
    Amsterdam, 1100 DD, Netherlands
  • Pracownia Żywienia Klinicznego
    Olsztyn, 10-651, Poland
  • Samodzielny Publiczny Szpital Kliniczny-Im.prof W.Orłowskiego CMKP
    Warsaw, 00-416, Poland
  • Hope Hospital
    Salford, Greater Manchester M68HD, United Kingdom
  • St. Mark's Hospital
    Harrow, HA13UJ, United Kingdom
09

References and documents

Publications

  • Dudrick SJ, Latifi R, Fosnocht DE. Management of the short-bowel syndrome. Surg Clin North Am. 1991 Jun;71(3):625-43. doi: 10.1016/s0039-6109(16)45438-1. PubMed 1904648 ↗
  • Rombeau JL, Rolandelli RH. Enteral and parenteral nutrition in patients with enteric fistulas and short bowel syndrome. Surg Clin North Am. 1987 Jun;67(3):551-71. doi: 10.1016/s0039-6109(16)44232-5. PubMed 3109044 ↗
  • Shanbhogue LK, Molenaar JC. Short bowel syndrome: metabolic and surgical management. Br J Surg. 1994 Apr;81(4):486-99. doi: 10.1002/bjs.1800810404. PubMed 8205419 ↗
  • Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology. 1997 Nov;113(5):1767-78. doi: 10.1053/gast.1997.v113.pm9352883. PubMed 9352883 ↗
  • Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011 Jul;60(7):902-14. doi: 10.1136/gut.2010.218271. Epub 2011 Feb 11. PubMed 21317170 ↗
  • Fujioka K, Jeejeebhoy K, Pape UF, Li B, Youssef NN, Schneider SM. Patients With Short Bowel on Narcotics During 2 Randomized Trials Have Abdominal Complaints Independent of Teduglutide. JPEN J Parenter Enteral Nutr. 2017 Nov;41(8):1419-1422. doi: 10.1177/0148607116663481. Epub 2016 Aug 9. PubMed 27507402 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Jul 2007, 37 months.

Results were first posted in Jul 2013, 6 years after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 37 months is close to that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2004
First posted
Apr 14, 2004
StartActual
May 25, 2004
Primary completionActual
Jul 6, 2007
CompletionActual
Jul 6, 2007
Results first posted
Jul 15, 2013
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00081458
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 14, 2004
Start date
May 25, 2004
Primary completion
Jul 6, 2007
Completion
Jul 6, 2007
Results posted
Jul 15, 2013
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion